KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Depreciation & Amortization (CF) (2016 - 2025)

Regeneron Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 17 years, most recently at $145.0 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $145.0 million for Q4 2025, up 14.72% from a year ago — trailing twelve months through Dec 2025 was $543.7 million (up 12.59% YoY), and the annual figure for FY2025 was $543.7 million, up 12.59%.
  • Depreciation & Amortization (CF) for Q4 2025 was $145.0 million at Regeneron Pharmaceuticals, up from $136.7 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for REGN hit a ceiling of $145.0 million in Q4 2025 and a floor of $67.4 million in Q1 2021.
  • Median Depreciation & Amortization (CF) over the past 5 years was $104.2 million (2023), compared with a mean of $103.8 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): grew 4.64% in 2022 and later surged 38.58% in 2023.
  • Regeneron Pharmaceuticals' Depreciation & Amortization (CF) stood at $74.5 million in 2021, then skyrocketed by 34.36% to $100.1 million in 2022, then grew by 12.89% to $113.0 million in 2023, then rose by 11.86% to $126.4 million in 2024, then rose by 14.72% to $145.0 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $145.0 million (Q4 2025), $136.7 million (Q3 2025), and $135.1 million (Q2 2025) per Business Quant data.